First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03893-z
Abstract: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. The clinical value of repeat rebiopsy in… read more here.
Keywords: rebiopsy; lung; first rebiopsy; repeat rebiopsy ... See more keywords
An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2022.2050213
Abstract: ABSTRACT Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can significantly improve patient prognosis when used on patients with EGFR-mutant non-small cell lung cancer (NSCLC), but those patients often develop acquired resistance after 9–14… read more here.
Keywords: treatment; egfr t790m; t790m mutation;
Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001403
Abstract: Osimertinib is a third-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitizing mutations and acquired drug-resistant mutation T790M. Despite promising treatment benefits of osimertinib in first- and… read more here.
Keywords: cancer; t790m mutation; lung; small cell ... See more keywords
Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14272
Abstract: This study aimed to evaluate possible treatment strategies for patients with de novo T790M mutation‐positive (T790M+) non‐small‐cell lung cancer (NSCLC). read more here.
Keywords: t790m mutation; epidermal growth; growth factor; novo t790m ... See more keywords
Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
Sign Up to like & getrecommendations! Published in 2017 at "ESMO Open"
DOI: 10.1136/esmoopen-2016-000104
Abstract: Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation… read more here.
Keywords: t790m mutation; mutation egfr; treatment; leptomeningeal carcinomatosis ... See more keywords
Treatment of Leptomeningeal Metastases in a Patient with Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
Sign Up to like & getrecommendations! Published in 2017 at "Case Reports in Oncology"
DOI: 10.1159/000480452
Abstract: Background: Leptomeningeal metastasis (LM) is an uncommon complication in patients with solid tumors, associated with poor survival. However, LM appears to be more frequent in lung cancer patients with EGFR mutations, posing a unique clinical… read more here.
Keywords: egfr t790m; lung cancer; t790m mutation; harboring egfr ... See more keywords
Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Medical Case Reports"
DOI: 10.1186/s13256-024-04706-w
Abstract: First- and second-generation anti-epithelial growth factor receptor tyrosine kinase inhibitors have shown great efficacy in the treatment of advanced adenocarcinoma with epithelial growth factor receptor mutations, but this efficacy is limited by certain resistance mechanisms,… read more here.
Keywords: complete response; t790m mutation; case; mutation ... See more keywords
Detecting T790M mutation of tissue and plasma ctDNA samples by ARMS in EGFR-mutant NSCLC patients after disease progression.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20625
Abstract: e20625Background: T790M mutation is the most common mechanism of acquired EGFR TKI resistance. The use of T790M-targeted EGFR TKIs needs re-biopsy to confirm the existence of sensitive mutation. Pe... read more here.
Keywords: tissue plasma; detecting t790m; plasma ctdna; t790m mutation ... See more keywords
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.14007
Abstract: Epidermal growth factor receptor (EGFR) T790M mutation has shown to be associated with the clinical outcomes of patients after initial EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy in EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, its… read more here.
Keywords: t790m mutation; egfr mutant; egfr tki; tki challenge ... See more keywords
The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16222
Abstract: Purpose The outcome of pretreatment epidermal growth factor receptor (EGFR) T790M mutation in EGFR mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) is controversial, this study aimed to evaluate… read more here.
Keywords: role pretreatment; patients treated; treated egfr; t790m mutation ... See more keywords
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2021 at "Translational Cancer Research"
DOI: 10.21037/tcr-21-223
Abstract: Background Osimertinib has been adopted as the standard therapy for T790M-mediated acquired resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small cell lung cancer (NSCLC). The detection of EGFR… read more here.
Keywords: cancer; t790m mutation; egfr t790m; abundance ... See more keywords